Skip to content
etf.net

PBPH

GradeBNASDAQ Global Market

Portfolio Building Block World Pharma and Biotech Index ETF

Themes · Portfolio Building Block ETFs · Inception 2025-11-24 · SEC filings

$28.46−0.29 (−1.01%)

As of Sep 23, 2026, 3:00 PM EDT

History starts Nov 25, 2025.History starts Nov 25, 2025.
Intraday session: down, 31 prints from 28.75 to 28.46. Range 28.36 to 28.83. Use the arrow keys to read each point.$28.40$28.60$28.8010 AM12 PM2 PM4 PM
Expense ratio
0.13%
Fund size
$1.0B
1Y return
—
Yield · Last 12 months
Data unavailable
Volume · 30D
0.1M sh
NAV per share
$28.51
52W range
low $24.18high $29.90

The ETF.net PBPH Grade

B

64/ 100

Rank 4 of 9 in Pharma & Therapeutics⁠

Confidence Medium

Six-pillar profile for PBPH. Scores out of 100: Cost 94, Risk 43, Mission not scored, Tradability 48, Holdings 42, Durability 49. Strongest: Cost (94). Weakest: Holdings (42). Based on 5 of 6 pillars.
F< 25
D≥ 25
C≥ 40
B≥ 55
A≥ 70

Score 64 of 100 sits in the B band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.

  • Cost

    What you pay to own it — the expense ratio plus trading frictions, ranked within its category.
    AScore 94
    Category rank1/9 · top 11%

  • Mission

    How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.
    Not scored
    —

  • Risk

    How violently it can move — volatility, drawdown depth, and downside capture versus its category.
    CScore 43
    Category rank6/9 · mid-pack

  • Tradability

    How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.
    CScore 48
    Category rank6/9 · mid-pack

  • Holdings

    What it actually owns — the quality, breadth, and concentration of the underlying portfolio.
    CScore 42
    Category rank6/9 · mid-pack

  • Durability

    Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.
    CScore 49
    Category rank6/9 · mid-pack

Graded as of Sep 22, 2026 · Based on 5 of 6 pillars

Our read on PBPH

ETF.net Research

BMost biotech funds stop at the US border. PBPH buys the developed world's drug complex, pharma and biotech together, through a plain index fund charging 0.13%.

Stated mandate

The Fund seeks to track, before fees and expenses, the performance of the BITA Global Pharma and Biotech Select Index.

Why people hold it

  1. 010.13% a year, in a global thematic aisle where the typical fund charges several times that. Fee drag is about as small as this shelf gets.
  2. 02Pharma and biotech under one ticker, global rather than US-only, so overseas drugmakers sit alongside the American names.portfoliobuildingblocketfs.com
  3. 03Straight index replication inside an ordinary 1940 Act fund. Published rules do the picking, not a manager's hunch.
  4. 04Cheap build plus workable trading puts it among the stronger implementations in its global thematic peer group.

Worth knowing

  1. 01One industry, one storyline. Drug pricing rules, patent cliffs and trial readouts swing this basket in ways the broad market does not feel.
  2. 02Launched in late 2025, so there is no long live record showing how closely it hugs the index across a full cycle.
  3. 03Cash comes back once or twice a year, not monthly. This is an exposure holding, not an income schedule.

PBPH Holdings

As of Sep 20, 2026, 9:24 AM
Asset class
Stocks
Holdings
—
Top-10 weight
61%
Largest holding
LLY.TO14.7%

Geography

  • United States74.60%
  • Switzerland5.39%
  • United Kingdom4.69%
  • Japan4.66%
  • France2.35%
  • Germany1.87%
  • Australia1.73%
  • Netherlands1.54%
  • Other countries (5)3.17%

Developed 94% · Emerging 6% of the foreign sleeve

The fund’s holdings, weight-ordered — page 1 of 4.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001LLY.TOELI LILLY & CO14.65%131,060$151M6
002JNJJOHNSON & JOHNSON9.80%373,986$101M521
003ABBVABBVIE INC7.03%274,675$73M511
004MRKMERCK & CO. INC.5.45%381,470$56M506
005—ROCHE HOLDING AG4.58%107,746$47M4
006AMGNAMGEN INC4.37%118,719$45M470
007GILDGILEAD SCIENCES INC4.18%285,722$43M482
008NVSNOVARTIS AG-REG3.85%282,037$40M49
009AZN.LASTRAZENECA PLC3.64%225,981$38M164
010PFE.BAPFIZER INC3.52%1,311,349$36M8
011—NOVO NORDISK A/S-B3.05%733,652$31M5
012VRTXVERTEX PHARMACEUTICALS INC2.92%58,247$30M417
013BMYBRISTOL-MYERS SQUIBB CO2.86%469,541$30M460
014—GSK PLC2.11%857,162$22M5
015SNYSANOFI2.10%249,868$22M35

Showing 1–15 of 55 holdings

PBPH Performance

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

PBPH$11,391
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,430
Dec 31, 2025 to Sep 22, 2026. PBPH $11,391. SPY $11,430. Use the arrow keys to read each point.$9,092$10,550$12,008Dec 2025May 2026Sep 2026

Dec 31, 2025 – Sep 22, 2026

Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for PBPH. Periods over one year show the average yearly return.
PeriodPBPH
Year to date+13.9%
1 month−2.8%
3 months+12.5%
1 yearFund is under 1 year old—
3 yearsFund is under 3 years old—per year
5 yearsFund is under 5 years old—per year
10 yearsFund is under 10 years old—per year

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for PBPH
YearReturn barPBPH
2026 YTD+13.9%
2025+0.7%

History from Nov 25, 2025

PBPH in the news

ETF.net Research hasn’t filed on PBPH yet — coverage lands here as it’s written.

PBPH Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Sep 22, 2026.
Data unavailableLast 12 months
Payout per share
Data unavailableLast 12 months
Last payment
$0.02 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Irregular

Distribution data unavailable.

Distribution history

2025–2026

One bar per payment. 1 payment from 2025 to 2026 YTD. Dec 24, 2025 $0.02. Use the arrow keys to read each point.20252026YTD
Ex-datePay dateAmount per share
Dec 24, 2025Dec 26, 2025$0.02

PBPH Risk

How much the fund’s monthly returns vary, scaled to a year.
—
Launched Nov 2025; fills in after 12 months
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
—
Launched Nov 2025; fills in after 12 months
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
—
Launched Nov 2025; fills in after 12 months
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.05
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

PBPH Cost

Expense ratio0.13%
  • The middle half of Pharma & Therapeutics funds
  • Median 0.58%

No Pharma & Therapeutics fund charges less.

PBPH costs $13.00 a year on $10,000. The median Pharma & Therapeutics fund costs $58.00.